Addus HomeCare (NASDAQ:ADUS) Releases Earnings Results, Beats Expectations By $0.02 EPS

Addus HomeCare (NASDAQ:ADUS) announced its quarterly earnings data on Monday. The company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.28 by $0.02, Briefing.com reports. Addus HomeCare had a return on equity of 9.81% and a net margin of 6.18%. The company had revenue of $289.80 million for the quarter, compared to the consensus estimate of $289.42 million. During the same quarter in the prior year, the company posted $1.03 EPS. Addus HomeCare’s quarterly revenue was up 7.1% on a year-over-year basis.

Addus HomeCare Price Performance

Shares of NASDAQ ADUS opened at $130.01 on Wednesday. Addus HomeCare has a 1-year low of $81.51 and a 1-year high of $136.12. The business has a fifty day moving average price of $129.77 and a 200 day moving average price of $120.85. The stock has a market capitalization of $2.35 billion, a P/E ratio of 28.41, a price-to-earnings-growth ratio of 2.29 and a beta of 1.04.

Wall Street Analysts Forecast Growth

ADUS has been the topic of several recent analyst reports. Oppenheimer raised their price target on shares of Addus HomeCare from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Monday, September 23rd. TD Cowen lifted their price target on shares of Addus HomeCare from $128.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Stephens reissued an “overweight” rating and issued a $138.00 price objective on shares of Addus HomeCare in a research note on Tuesday, August 6th. Macquarie reaffirmed an “outperform” rating and set a $139.00 target price on shares of Addus HomeCare in a research report on Monday. Finally, KeyCorp initiated coverage on Addus HomeCare in a research report on Friday, October 11th. They set an “overweight” rating and a $150.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.38.

Insider Buying and Selling at Addus HomeCare

In other Addus HomeCare news, EVP Michael D. Wattenbarger sold 21,917 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $133.29, for a total transaction of $2,921,316.93. Following the completion of the sale, the executive vice president now directly owns 7,215 shares of the company’s stock, valued at approximately $961,687.35. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Michael D. Wattenbarger sold 21,917 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $133.29, for a total transaction of $2,921,316.93. Following the transaction, the executive vice president now directly owns 7,215 shares of the company’s stock, valued at approximately $961,687.35. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Esteban Lopez sold 500 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $130.03, for a total value of $65,015.00. Following the completion of the sale, the director now directly owns 3,866 shares of the company’s stock, valued at $502,695.98. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,917 shares of company stock worth $3,050,082 over the last quarter. Insiders own 4.60% of the company’s stock.

Addus HomeCare Company Profile

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.